Monopar Therapeutics Inc. ( Monopar, the Company, we, us, and our and similar terms mean Monopar Therapeutics Inc. and its subsidiaries except where the context otherwise requires) is a clinical-stage biopharmaceutical company developing an innovative treatment for Wilson disease and novel radiopharmaceuticals for oncology. Our Wilson disease product candidate is ALXN1840, a late-stage, investi…
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (FY)
$0.00
Net Income (TTM)
-$15M
▲ +12.0% YoY
Op. Margin
—
ROIC
-12.64%
▲ +28.4pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$10M
▼ -90.5% YoY
Net Debt
-$105M
Net Cash Position
Cash & Equiv.
$105M
Continue Research